Molecular Pharmacodynamics, Clinical Therapeutics, and Pharmacokinetics of Topiramate
- 14 May 2008
- journal article
- review article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 14 (2) , 120-142
Abstract
Topiramate (TPM; TOPAMAX®) is a broad‐spectrum antiepileptic drug (AED) that is approved in many world markets for preventing or reducing the frequency of epileptic seizures (as monotherapy or adjunctive therapy), and for the prophylaxis of migraine. TPM, a sulfamate derivative of the naturally occurring sugar D‐fructose, possesses several pharmacodynamic properties that may contribute to its clinically useful attributes, and to its observed adverse effects. The sulfamate moiety is essential, but not sufficient, for its pharmacodynamic properties. In this review, we discuss the known pharmacodynamic and pharmacokinetic properties of TPM, as well as its various clinically beneficial and adverse effects.Keywords
This publication has 248 references indexed in Scilit:
- The Role of Hippocampal GluR1 and GluR2 Receptors in Manic-Like BehaviorJournal of Neuroscience, 2008
- Topiramate reduced sweat secretion and aquaporin-5 expression in sweat glands of miceLife Sciences, 2007
- Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentinExpert Opinion on Drug Safety, 2007
- Age‐dependent Effects of Topiramate on the Acquisition and the Retention of Rapid KindlingEpilepsia, 2007
- Ocular Adverse Effects Associated with Systemic MedicationsDrugs, 2007
- Suicidality and Antiepileptic DrugsDrug Safety, 2007
- Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled studyInternational Journal of Obesity, 2006
- Pharmacotherapy for ObesityDrugs, 2005
- Pharmacokinetic Interactions of TopiramateClinical Pharmacokinetics, 2004
- Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER)Life Sciences, 1996